AI in Clinical Trials Market Report 2026

The AI in clinical trials market size has grown exponentially in recent years. It will grow from $9.16 billion in 2025 to $13.08 billion in 2026 at a compound annual growth rate (CAGR) of 42.8%. The growth in the historic period can be attributed to rising clinical trial complexity, increasing R&D expenditure, demand for faster drug development, growth in clinical data volumes, limitations of traditional trial methods.

The AI in clinical trials market size is expected to see exponential growth in the next few years. It will grow to $54.71 billion in 2030 at a compound annual growth rate (CAGR) of 43%. The growth in the forecast period can be attributed to expansion of decentralized clinical trials, increasing adoption of real world evidence, growth of precision medicine, rising regulatory acceptance of AI tools, advancements in healthcare analytics. Major trends in the forecast period include AI driven patient recruitment, predictive trial outcome modeling, automated clinical data analysis, remote patient monitoring integration, adaptive trial design adoption.

Rising cases of chronic and infectious diseases are anticipated to drive the expansion of the AI in clinical trials market in the coming years. A chronic disease is defined as a condition that persists for three months or longer and often worsens over time. Artificial intelligence in clinical trials plays a crucial role in supporting the development of new drugs for the treatment of chronic illnesses. For example, in August 2024, Macmillan Cancer Support, a UK-based organization, reported that over 3 million people in the UK were living with cancer in 2024, a number expected to rise to 3.5 million by 2025, 4 million by 2030, and 5.3 million by 2040. As a result, the growing incidence of chronic and infectious diseases is contributing to the growth of the AI in the clinical trials market.

Leading companies operating in the AI in clinical trials market are increasingly turning to strategic partnerships to provide advanced research tools and improve workflow efficiency, leading to shorter timelines and higher patient enrollment. Strategic partnerships involve companies combining their strengths and resources to achieve shared objectives and mutual success. For instance, in February 2023, a US-based pharmaceutical commercial company entered into a partnership with Haystack Health, a US-based software development firm. Through this collaboration, they seek to utilize AI and Natural Language Processing (NLP) to accelerate clinical trials, enhance patient recruitment, and lower screen failure rates by using clinical AI and pre-screening services, which are often time-consuming and costly.

In April 2024, Clario, a US-based company specializing in data solutions and clinical trial technologies, acquired ArtiQ for an undisclosed sum. Through this acquisition, Clario aims to strengthen its artificial intelligence-driven respiratory solutions and further enhance its overall AI and machine learning capabilities across clinical trial endpoints. ArtiQ is a Belgium-based provider of AI-powered software that supports the diagnosis, monitoring, and optimization of respiratory clinical trials using advanced machine-learning models.

Major companies operating in the AI in clinical trials market are ConcertAI Inc.; Owkin Inc.; AiCure Technologies Inc.; Ardigen S.A.; Unlearn.AI Inc.; PathAI Inc.; Exscientia plc; VeriSIM Life Inc.; Envisagenics Inc.; NURITAS Limited; BioSymetrics Inc.; Trials.AI Inc.; IQVIA Holdings Inc.; Euretos B.V.; Saama Technologies LLC; Deep 6 AI Inc.; Medidata Solutions Inc.; Antidote Technologies Inc.; Castor EDC B.V.; TrialSpark Inc.; Phesi S.A.; CluePoints NV.

North America was the largest region in the AI in clinical trials market in 2025. The regions covered in the AI in clinical trials market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the AI in clinical trials market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the AI in clinical trials market by increasing costs for imported computing infrastructure, data storage systems, and monitoring devices. These effects are more visible in technology intensive trial operations across North America, Europe, and parts of Asia Pacific. Higher costs have influenced trial budgets and technology sourcing decisions. At the same time, tariffs are encouraging cloud based and software driven trial platforms. This shift is strengthening digital trial ecosystems and supporting localized innovation in clinical research technologies.

The AI in clinical trials market research report is one of a series of new reports that provides AI in clinical trials market statistics, including AI in clinical trials industry global market size, regional shares, competitors with a AI in clinical trials market share, detailed AI in clinical trials market segments, market trends and opportunities, and any further data you may need to thrive in the AI in clinical trials industry. This AI in clinical trials market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

AI in clinical trials involves the application of artificial intelligence (AI) technologies and techniques in the planning, design, execution, and analysis of clinical trials. Clinical trials are rigorous research studies that assess the safety and effectiveness of medical interventions, such as new drugs, medical devices, or treatment protocols, in human subjects.

The primary offerings for AI in clinical trials include software and services. AI in clinical trial services encompasses the investigation and generation of insights from past and current clinical trials. Various processes, including trial design, patient selection, site selection, and patient monitoring, leverage technologies such as machine learning, deep learning, supervised learning, and other machine learning technologies. These applications span across various medical fields such as oncology, neurological diseases, cardiovascular diseases, metabolic diseases, infectious diseases, and immunology diseases. The end-users of AI in clinical trials include pharmaceuticals and biotechnology companies, contract research organizations, and others.

The AI in clinical trials market consists of revenues earned by entities by providing AI software solutions and platforms designed to assist in various aspects of clinical trials, such as trial design, patient recruitment, data collection, monitoring, and analysis, data analytics and insights, predictive modeling and simulation, regulatory compliance, and safety monitoring. The market value includes the value of related goods sold by the service provider or included within the service offering. The AI in clinical trials also includes sales of computer vision technology, cognitive computing, and machine translation technologies which are used in providing clinical trials. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.